Centre d'Information et de documentation du CRA Rhône-Alpes
CRA
Informations pratiques
-
Adresse
Centre d'information et de documentation
du CRA Rhône-Alpes
Centre Hospitalier le Vinatier
bât 211
95, Bd Pinel
69678 Bron CedexHoraires
Lundi au Vendredi
9h00-12h00 13h30-16h00Contact
Tél: +33(0)4 37 91 54 65
Mail
Fax: +33(0)4 37 91 54 37
-
Résultat de la recherche
5 recherche sur le mot-clé 'antidepressants'
Affiner la recherche Générer le flux rss de la recherche
Partager le résultat de cette recherche Faire une suggestion
Suicidality in Adults with Autism Spectrum Disorder: The Role of Depressive Symptomatology, Alexithymia, and Antidepressants / Andreia P. COSTA in Journal of Autism and Developmental Disorders, 50-10 (October 2020)
[article]
Titre : Suicidality in Adults with Autism Spectrum Disorder: The Role of Depressive Symptomatology, Alexithymia, and Antidepressants Type de document : Texte imprimé et/ou numérique Auteurs : Andreia P. COSTA, Auteur ; Cathia LOOR, Auteur ; Georges STEFFGEN, Auteur Article en page(s) : p.3585-3597 Langues : Anglais (eng) Mots-clés : Asd Alexithymia Antidepressants Depression Risk factors Suicidality Index. décimale : PER Périodiques Résumé : People with autism spectrum disorder (ASD) have an increased risk of suicidality. However, the risk factors remain under-investigated. This study explored factors that increase suicidality risk in ASD. Through an online survey, 150 adults with ASD were compared to 189 control adults. Autistic traits, depressive symptomatology, alexithymia, and antidepressant intake were assessed on their contribution predicting suicidality. Among people with ASD, 63% scored above the cutoff for high suicidality risk. Increased autistic traits, depressive symptomatology, and antidepressant intake significantly predicted suicidality. Furthermore, among those with high levels of autistic traits, the risk of suicidality was increased if they also had high levels of alexithymia. These results highlight the importance of considering depression, antidepressants, and alexithymia to prevent suicidality in ASD. En ligne : http://dx.doi.org/10.1007/s10803-020-04433-3 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=432
in Journal of Autism and Developmental Disorders > 50-10 (October 2020) . - p.3585-3597[article] Suicidality in Adults with Autism Spectrum Disorder: The Role of Depressive Symptomatology, Alexithymia, and Antidepressants [Texte imprimé et/ou numérique] / Andreia P. COSTA, Auteur ; Cathia LOOR, Auteur ; Georges STEFFGEN, Auteur . - p.3585-3597.
Langues : Anglais (eng)
in Journal of Autism and Developmental Disorders > 50-10 (October 2020) . - p.3585-3597
Mots-clés : Asd Alexithymia Antidepressants Depression Risk factors Suicidality Index. décimale : PER Périodiques Résumé : People with autism spectrum disorder (ASD) have an increased risk of suicidality. However, the risk factors remain under-investigated. This study explored factors that increase suicidality risk in ASD. Through an online survey, 150 adults with ASD were compared to 189 control adults. Autistic traits, depressive symptomatology, alexithymia, and antidepressant intake were assessed on their contribution predicting suicidality. Among people with ASD, 63% scored above the cutoff for high suicidality risk. Increased autistic traits, depressive symptomatology, and antidepressant intake significantly predicted suicidality. Furthermore, among those with high levels of autistic traits, the risk of suicidality was increased if they also had high levels of alexithymia. These results highlight the importance of considering depression, antidepressants, and alexithymia to prevent suicidality in ASD. En ligne : http://dx.doi.org/10.1007/s10803-020-04433-3 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=432 Annual Research Review: Maternal antidepressant use during pregnancy and offspring neurodevelopmental problems - a critical review and recommendations for future research / A. C. SUJAN in Journal of Child Psychology and Psychiatry, 60-4 (April 2019)
[article]
Titre : Annual Research Review: Maternal antidepressant use during pregnancy and offspring neurodevelopmental problems - a critical review and recommendations for future research Type de document : Texte imprimé et/ou numérique Auteurs : A. C. SUJAN, Auteur ; A. S. OBERG, Auteur ; P. D. QUINN, Auteur ; B. M. D'ONOFRIO, Auteur Article en page(s) : p.356-376 Langues : Anglais (eng) Mots-clés : Antidepressants attention-deficit/hyperactivity disorder autism spectrum disorder causal inference neurodevelopmental problems pregnancy prenatal antidepressant exposure Index. décimale : PER Périodiques Résumé : Children of women treated with antidepressants during pregnancy are more likely to develop neurodevelopmental problems than are unexposed children. Associations between prenatal antidepressant exposure and neurodevelopmental problems could reflect a causal effect or could be partially or fully explained by other factors that differ between exposed and unexposed offspring, including having mothers with conditions requiring antidepressant treatment (e.g. depression), environmental risk factors, and/or genetic risk factors shared across disorders. This translational review aims to provide a brief overview of findings from rodent experiments and critically evaluate observational studies in humans to assess the extent to which associations between prenatal antidepressant exposure and neurodevelopmental problems are due to causal mechanisms versus other influences. We focus our review on two important neurodevelopmental outcomes - autism spectrum disorder (ASD) and attention-deficit/hyperactivity disorder (ADHD). In general, rodent studies have reported adverse effects of perinatal antidepressant exposure on neurodevelopment. Between-species differences raise questions about the generalizability of these findings to humans. Indeed, converging evidence from studies using multiple designs and approaches suggest that observed associations between prenatal antidepressant exposure and neurodevelopmental problems in humans are largely due to confounding factors. We also provide specific recommendations for future research. Animal research should explicitly evaluate the impact of timing of exposure and dosage of medications, as well as better map outcome measures in rodents to human neurodevelopmental problems. Observational studies should investigate specific confounding factors, specific antidepressant drugs and classes, the potential impact of timing of exposure, and a wider range of other potential offspring outcomes. The findings summarized in this review may help women and their doctors make informed decisions about antidepressant use during pregnancy by providing reassurance that use of these medications during pregnancy is unlikely to substantially increase the risk of ASD and ADHD. En ligne : https://dx.doi.org/10.1111/jcpp.13004 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=388
in Journal of Child Psychology and Psychiatry > 60-4 (April 2019) . - p.356-376[article] Annual Research Review: Maternal antidepressant use during pregnancy and offspring neurodevelopmental problems - a critical review and recommendations for future research [Texte imprimé et/ou numérique] / A. C. SUJAN, Auteur ; A. S. OBERG, Auteur ; P. D. QUINN, Auteur ; B. M. D'ONOFRIO, Auteur . - p.356-376.
Langues : Anglais (eng)
in Journal of Child Psychology and Psychiatry > 60-4 (April 2019) . - p.356-376
Mots-clés : Antidepressants attention-deficit/hyperactivity disorder autism spectrum disorder causal inference neurodevelopmental problems pregnancy prenatal antidepressant exposure Index. décimale : PER Périodiques Résumé : Children of women treated with antidepressants during pregnancy are more likely to develop neurodevelopmental problems than are unexposed children. Associations between prenatal antidepressant exposure and neurodevelopmental problems could reflect a causal effect or could be partially or fully explained by other factors that differ between exposed and unexposed offspring, including having mothers with conditions requiring antidepressant treatment (e.g. depression), environmental risk factors, and/or genetic risk factors shared across disorders. This translational review aims to provide a brief overview of findings from rodent experiments and critically evaluate observational studies in humans to assess the extent to which associations between prenatal antidepressant exposure and neurodevelopmental problems are due to causal mechanisms versus other influences. We focus our review on two important neurodevelopmental outcomes - autism spectrum disorder (ASD) and attention-deficit/hyperactivity disorder (ADHD). In general, rodent studies have reported adverse effects of perinatal antidepressant exposure on neurodevelopment. Between-species differences raise questions about the generalizability of these findings to humans. Indeed, converging evidence from studies using multiple designs and approaches suggest that observed associations between prenatal antidepressant exposure and neurodevelopmental problems in humans are largely due to confounding factors. We also provide specific recommendations for future research. Animal research should explicitly evaluate the impact of timing of exposure and dosage of medications, as well as better map outcome measures in rodents to human neurodevelopmental problems. Observational studies should investigate specific confounding factors, specific antidepressant drugs and classes, the potential impact of timing of exposure, and a wider range of other potential offspring outcomes. The findings summarized in this review may help women and their doctors make informed decisions about antidepressant use during pregnancy by providing reassurance that use of these medications during pregnancy is unlikely to substantially increase the risk of ASD and ADHD. En ligne : https://dx.doi.org/10.1111/jcpp.13004 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=388 Practitioner Review: Therapeutics of unipolar major depressions in adolescents / I. M. GOODYER in Journal of Child Psychology and Psychiatry, 60-3 (March 2019)
[article]
Titre : Practitioner Review: Therapeutics of unipolar major depressions in adolescents Type de document : Texte imprimé et/ou numérique Auteurs : I. M. GOODYER, Auteur ; P. O. WILKINSON, Auteur Article en page(s) : p.232-243 Langues : Anglais (eng) Mots-clés : Depression adolescents antidepressants psychotherapies Index. décimale : PER Périodiques Résumé : BACKGROUND: Over the past two decades new and key randomized controlled trials have reported the efficacy, clinical and cost effectiveness of psychological and pharmacological treatments for adolescents with major depression. METHODS: The literature was searched through pubmed, psychinfo, scopus and web of science for randomized controlled trials of current major depression together with meta-analyses and systematic reviews of trials between 2000 and 2017. Those specific to the adolescent years (11-18 years) were taken as the primary source for this narrative review. Additional selected studies in adults were used to illustrate methodological issues. RESULTS: Manualized psychological therapies and the SSRI fluoxetine are more effective than active placebo in the treatment of major depressions. Mild to moderate illnesses attending community-based services are likely to benefit from psychological treatment alone. Moderately to severely ill patients attending clinic and hospital services are likely to benefit from monotherapies or combining psychological and pharmacological treatment. Antidepressants carry a small but significant side-effect risk including increased suicidality. Side effects from psychotherapies are somewhat lower but specific negative consequences remain less well characterized. There is some evidence that CBT-based approaches prevent onset of major depression episode in well adolescents at high-risk. Other psychological interventions have not been adequately studied. There has been only limited identification of treatment moderators and no clear understanding of therapeutic mechanisms. CONCLUSIONS: There is now a range of clinically effective treatments for depressed adolescents. Future research needs to reveal moderators of and mechanisms for individual differences to treatment response, determine psychotherapies of value for milder depressions, enhance our understanding of safety and side-effects for all treatments, and consider how to reduce and treat treatment-resistant cases. En ligne : https://dx.doi.org/10.1111/jcpp.12940 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=385
in Journal of Child Psychology and Psychiatry > 60-3 (March 2019) . - p.232-243[article] Practitioner Review: Therapeutics of unipolar major depressions in adolescents [Texte imprimé et/ou numérique] / I. M. GOODYER, Auteur ; P. O. WILKINSON, Auteur . - p.232-243.
Langues : Anglais (eng)
in Journal of Child Psychology and Psychiatry > 60-3 (March 2019) . - p.232-243
Mots-clés : Depression adolescents antidepressants psychotherapies Index. décimale : PER Périodiques Résumé : BACKGROUND: Over the past two decades new and key randomized controlled trials have reported the efficacy, clinical and cost effectiveness of psychological and pharmacological treatments for adolescents with major depression. METHODS: The literature was searched through pubmed, psychinfo, scopus and web of science for randomized controlled trials of current major depression together with meta-analyses and systematic reviews of trials between 2000 and 2017. Those specific to the adolescent years (11-18 years) were taken as the primary source for this narrative review. Additional selected studies in adults were used to illustrate methodological issues. RESULTS: Manualized psychological therapies and the SSRI fluoxetine are more effective than active placebo in the treatment of major depressions. Mild to moderate illnesses attending community-based services are likely to benefit from psychological treatment alone. Moderately to severely ill patients attending clinic and hospital services are likely to benefit from monotherapies or combining psychological and pharmacological treatment. Antidepressants carry a small but significant side-effect risk including increased suicidality. Side effects from psychotherapies are somewhat lower but specific negative consequences remain less well characterized. There is some evidence that CBT-based approaches prevent onset of major depression episode in well adolescents at high-risk. Other psychological interventions have not been adequately studied. There has been only limited identification of treatment moderators and no clear understanding of therapeutic mechanisms. CONCLUSIONS: There is now a range of clinically effective treatments for depressed adolescents. Future research needs to reveal moderators of and mechanisms for individual differences to treatment response, determine psychotherapies of value for milder depressions, enhance our understanding of safety and side-effects for all treatments, and consider how to reduce and treat treatment-resistant cases. En ligne : https://dx.doi.org/10.1111/jcpp.12940 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=385 Interactive Effects of Prenatal Antidepressant Exposure and Likely Gene Disrupting Mutations on the Severity of Autism Spectrum Disorder / S. ACKERMAN in Journal of Autism and Developmental Disorders, 47-11 (November 2017)
[article]
Titre : Interactive Effects of Prenatal Antidepressant Exposure and Likely Gene Disrupting Mutations on the Severity of Autism Spectrum Disorder Type de document : Texte imprimé et/ou numérique Auteurs : S. ACKERMAN, Auteur ; S. SCHOENBRUN, Auteur ; C. HUDAC, Auteur ; Raphael BERNIER, Auteur Article en page(s) : p.3489-3496 Langues : Anglais (eng) Mots-clés : Asd Antidepressants Autism Genetics Ssri Index. décimale : PER Périodiques Résumé : To examine the interactive effects of two proposed risk factors which may contribute to symptom severity of Autism Spectrum Disorder (ASD): prenatal antidepressant exposure and likely gene-disrupting (LGD) mutations. Participants included 2748 individuals with ASD from the Simons Simplex Collection. We examined the effects of prenatal antidepressant exposure, maternal depression, presence of an LGD mutation and their interaction on ASD severity. We found a significant interactive effect between antidepressant exposure and the presence of an LGD mutation on ASD severity in the ADOS and ADI-R verbal communication domains. We consider a "two-hit" model in which one variable lays the foundation for an initial risk which is compounded by a second variable. En ligne : http://dx.doi.org/10.1007/s10803-017-3246-6 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=324
in Journal of Autism and Developmental Disorders > 47-11 (November 2017) . - p.3489-3496[article] Interactive Effects of Prenatal Antidepressant Exposure and Likely Gene Disrupting Mutations on the Severity of Autism Spectrum Disorder [Texte imprimé et/ou numérique] / S. ACKERMAN, Auteur ; S. SCHOENBRUN, Auteur ; C. HUDAC, Auteur ; Raphael BERNIER, Auteur . - p.3489-3496.
Langues : Anglais (eng)
in Journal of Autism and Developmental Disorders > 47-11 (November 2017) . - p.3489-3496
Mots-clés : Asd Antidepressants Autism Genetics Ssri Index. décimale : PER Périodiques Résumé : To examine the interactive effects of two proposed risk factors which may contribute to symptom severity of Autism Spectrum Disorder (ASD): prenatal antidepressant exposure and likely gene-disrupting (LGD) mutations. Participants included 2748 individuals with ASD from the Simons Simplex Collection. We examined the effects of prenatal antidepressant exposure, maternal depression, presence of an LGD mutation and their interaction on ASD severity. We found a significant interactive effect between antidepressant exposure and the presence of an LGD mutation on ASD severity in the ADOS and ADI-R verbal communication domains. We consider a "two-hit" model in which one variable lays the foundation for an initial risk which is compounded by a second variable. En ligne : http://dx.doi.org/10.1007/s10803-017-3246-6 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=324 A preliminary study of pharmacogenetic biomarkers for individuals with autism and gastrointestinal dysfunction / A. E. SHINDLER in Research in Autism Spectrum Disorders, 71 (March 2020)
[article]
Titre : A preliminary study of pharmacogenetic biomarkers for individuals with autism and gastrointestinal dysfunction Type de document : Texte imprimé et/ou numérique Auteurs : A. E. SHINDLER, Auteur ; E. L. HILL-YARDIN, Auteur ; S. PETROVSKI, Auteur ; N. BISHOP, Auteur ; A. E. FRANKS, Auteur Article en page(s) : p.101516 Langues : Anglais (eng) Mots-clés : ASD Gastrointestinal dysfunction Pharmacogenetics Antidepressants Antipsychotics Index. décimale : PER Périodiques Résumé : Background Autism Spectrum Disorder (ASD) symptoms are commonly treated with a variety of pharmaceuticals which can have adverse side effects. A study of pharmacogenetic biomarkers for ASD medications and association with gastrointestinal (GI) dysfunction symptoms was conducted in individuals diagnosed with autism and/or GI dysfunction to provide further information on the genetic risk in relation to treatment effectiveness. Methods A total of sixty participants were recruited, 10 with autism and GI dysfunction, 21 with GI dysfunction (without autism) and 29 without autism or GI dysfunction (typical controls). Buccal cell samples were collected and sequenced. A GI dysfunction questionnaire which included questions regarding prescription of medications associated with treating ASD symptoms was provided to the participants. To calculate Odds Ratios and compare the average of risk allele expression frequency of the SNPS being investigated, the sequencing and questionnaire data were analyzed using the epiR package and Welch Two Sample T-tests, respectively, using the R statistics program. The Bonferroni correction was utilized to correct for multiple comparisions. Results People in the autism group were more likely to express the risk alleles for the Cytochrome P450 family 2 subfamily C member 9 rs1057910 and Solute Carrier family 6, member 2 rs3785143 SNPs; however, after the Bonferroni correction these findings were not statistically significant (CYP2C9 rs1057910, P?=?0.074; SLC6A2, rs3785143, P?=?0.4218). Conclusions Further research is warranted to reveal the potential use of CYP2C9 and SLC6A2 SNP expression as pharmacogenetic biomarkers to determine the most appropriate medication for individuals with autism and/or GI dysfunction. En ligne : https://doi.org/10.1016/j.rasd.2020.101516 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=417
in Research in Autism Spectrum Disorders > 71 (March 2020) . - p.101516[article] A preliminary study of pharmacogenetic biomarkers for individuals with autism and gastrointestinal dysfunction [Texte imprimé et/ou numérique] / A. E. SHINDLER, Auteur ; E. L. HILL-YARDIN, Auteur ; S. PETROVSKI, Auteur ; N. BISHOP, Auteur ; A. E. FRANKS, Auteur . - p.101516.
Langues : Anglais (eng)
in Research in Autism Spectrum Disorders > 71 (March 2020) . - p.101516
Mots-clés : ASD Gastrointestinal dysfunction Pharmacogenetics Antidepressants Antipsychotics Index. décimale : PER Périodiques Résumé : Background Autism Spectrum Disorder (ASD) symptoms are commonly treated with a variety of pharmaceuticals which can have adverse side effects. A study of pharmacogenetic biomarkers for ASD medications and association with gastrointestinal (GI) dysfunction symptoms was conducted in individuals diagnosed with autism and/or GI dysfunction to provide further information on the genetic risk in relation to treatment effectiveness. Methods A total of sixty participants were recruited, 10 with autism and GI dysfunction, 21 with GI dysfunction (without autism) and 29 without autism or GI dysfunction (typical controls). Buccal cell samples were collected and sequenced. A GI dysfunction questionnaire which included questions regarding prescription of medications associated with treating ASD symptoms was provided to the participants. To calculate Odds Ratios and compare the average of risk allele expression frequency of the SNPS being investigated, the sequencing and questionnaire data were analyzed using the epiR package and Welch Two Sample T-tests, respectively, using the R statistics program. The Bonferroni correction was utilized to correct for multiple comparisions. Results People in the autism group were more likely to express the risk alleles for the Cytochrome P450 family 2 subfamily C member 9 rs1057910 and Solute Carrier family 6, member 2 rs3785143 SNPs; however, after the Bonferroni correction these findings were not statistically significant (CYP2C9 rs1057910, P?=?0.074; SLC6A2, rs3785143, P?=?0.4218). Conclusions Further research is warranted to reveal the potential use of CYP2C9 and SLC6A2 SNP expression as pharmacogenetic biomarkers to determine the most appropriate medication for individuals with autism and/or GI dysfunction. En ligne : https://doi.org/10.1016/j.rasd.2020.101516 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=417